首页> 美国卫生研究院文献>Blood Advances >Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells
【2h】

Urokinase plasminogen activator and receptor promote collagen-induced arthritis through expression in hematopoietic cells

机译:尿激酶纤溶酶原激活物和受体通过在造血细胞中表达促进胶原诱导的关节炎

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

The plasminogen activation (PA) system has been implicated in driving inflammatory arthritis, but the precise contribution of PA system components to arthritis pathogenesis remains poorly defined. Here, the role of urokinase plasminogen activator (uPA) and its cognate receptor (uPAR) in the development and severity of inflammatory joint disease was determined using uPA- and uPAR-deficient mice inbred to the strain DBA/1J, a genetic background highly susceptible to collagen-induced arthritis (CIA). Mice deficient in uPA displayed a near-complete amelioration of macroscopic and histological inflammatory joint disease following CIA challenge. Similarly, CIA-challenged uPAR-deficient mice exhibited significant amelioration of arthritis incidence and severity. Reduced disease development in uPA-deficient and uPAR-deficient mice was not due to an altered adaptive immune response to the CIA challenge. Reciprocal bone marrow transplant studies indicated that uPAR-driven CIA was due to expression by hematopoietic-derived cells, as mice with uPAR-deficient bone marrow challenged with CIA developed significantly reduced macroscopic and histological joint disease as compared with mice with uPAR expression limited to non–hematopoietic-derived cells. These findings indicate a fundamental role for uPAR-expressing hematopoietic cells in driving arthritis incidence and progression. Thus, uPA/uPAR-mediated cell surface proteolysis and/or uPAR-mediated signaling events promote inflammatory joint disease, indicating that disruption of this key proteolytic/signaling system may provide a novel therapeutic strategy to limit clinical arthritis.
机译:纤溶酶原激活(PA)系统与炎症性关节炎的发生有关,但PA系统组分对关节炎发病机理的精确贡献仍然不清楚。在这里,使用近交品系DBA / 1J的uPA和uPAR缺陷型小鼠,确定了尿激酶纤溶酶原激活剂(uPA)及其关联受体(uPAR)在炎性关节疾病的发展和严重程度中的作用。胶原诱导的关节炎(CIA)。 CIA攻击后,uPA缺乏的小鼠在宏观和组织炎症性关节疾病方面表现出近乎完全的改善。同样,CIA挑战的uPAR缺陷小鼠表现出明显的关节炎发病率和严重程度改善。 uPA缺陷型和uPAR缺陷型小鼠中疾病发展的减少并不是由于对CIA攻击的适应性免疫反应发生了改变。相互进行的骨髓移植研究表明,uPAR驱动的CIA是由造血细胞表达引起的,因为与受uPAR表达限制为非–造血细胞。这些发现表明表达uPAR的造血细胞在驱动关节炎发生和发展中的基本作用。因此,uPA / uPAR介导的细胞表面蛋白水解和/或uPAR介导的信号传导事件促进了炎症性关节疾病,表明该关键蛋白水解/信号系统的破坏可能提供一种限制临床关节炎的新型治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号